The stock of Enzo Biochem, Inc. (NYSE:ENZ) hit a new 52-week high and has $18.22 target or 164.00% above today’s $6.90 share price. The 9 months bullish chart indicates low risk for the $326.26 million company. The 1-year high was reported on Nov, 17 by Barchart.com. If the $18.22 price target is reached, the company will be worth $535.07 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 108,091 shares traded hands. Enzo Biochem, Inc. (NYSE:ENZ) has risen 39.88% since April 15, 2016 and is uptrending. It has outperformed by 35.26% the S&P500.
According to Zacks Investment Research, “Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company’s three wholly-owned subsidiaries–Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company’s research is the development of products based on two technology platforms — genetic modulation and immune modulation.”
Insitutional Activity: The institutional sentiment decreased to 1.38 in 2016 Q2. Its down 0.12, from 1.5 in 2016Q1. The ratio dropped, as 16 funds sold all Enzo Biochem, Inc. shares owned while 24 reduced positions. 25 funds bought stakes while 30 increased positions. They now own 24.06 million shares or 13.07% more from 21.28 million shares in 2016Q1.
Manufacturers Life Ins The holds 0% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ) for 153,951 shares. Tfs Cap Ltd last reported 0.16% of its portfolio in the stock. Kopp Investment Advisors Ltd Liability Company reported 684,359 shares or 2.17% of all its holdings. Blackrock Invest Mngmt Limited Company accumulated 151,049 shares or 0% of the stock. The New York-based Comml Bank Of Ny Mellon Corp has invested 0% in Enzo Biochem, Inc. (NYSE:ENZ). Jacobs Levy Equity Mngmt last reported 0% of its portfolio in the stock. Advisory Services Networks Limited Liability Corporation last reported 0% of its portfolio in the stock. Clarivest Asset Mngmt Ltd Liability Corporation last reported 265,503 shares in the company. Renaissance Techs Ltd Liability holds 0.02% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ) for 1.87M shares. Federated Investors Pa accumulated 1,624 shares or 0% of the stock. Millrace Asset Grp Inc owns 131,956 shares or 1.28% of their US portfolio. Spark Inv Management Ltd Limited Liability Company, a New York-based fund reported 99,200 shares. Eagle Glob Advisors Ltd Liability owns 62,210 shares or 0.01% of their US portfolio. Hudock Cap Grp Inc Incorporated Limited Liability Corp has 0% invested in the company for 380 shares. Rhumbline Advisers has 38,985 shares for 0% of their US portfolio.
More recent Enzo Biochem, Inc. (NYSE:ENZ) news were published by: Businesswire.com which released: “Enzo Biochem Demonstrates Greater Sensitivity of Its AmpiProbeâ„¢ Platform for …” on October 29, 2015. Also Prnewswire.com published the news titled: “Lone Star Value Issues Open Letter to Shareholders of Enzo Biochem, Inc.” on December 22, 2015. Businesswire.com‘s news article titled: “Enzo Biochem Reaches $10 Million Patent Infringement Settlement with …” with publication date: October 13, 2015 was also an interesting one.
ENZ Company Profile
Enzo Biochem, Inc. (Enzo), incorporated on August 13, 1976, is a bioscience firm focusing on delivering and applying technology capabilities to produce services and products. The Company’s divisions include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. The Company’s products in the development pipeline include a range of assays for detection of various women’s health infectious agents, as well as for use in the identification of pathogens for other markets. The Company’s product development activity and pipeline include products, such as HPV E6/E7 Detection, HCV Viral Load, Cardiac Marker, IHC Detection, TH1/TH2, Cancer AB Panel and Cancer Marker Panel. The Firm has developed a portfolio of technologies with a range of research, diagnostic and therapeutic applications. The Company’s technologies include Gene analysis technology, Amplification, Flow Cytometry, Non-radioactive labeling and detection and Formats.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.